The Dutch rare disease company Pharming Group NV has embarked on expansion by acquiring an exclusive global license to CDZ173 (leniolisib), a late-stage small-molecule drug for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immune deficiency, in return for an upfront payment of $20m to Novartis AG as well as potential milestone and royalty payments.
CDZ173 is currently in a pivotal Phase II/III clinical trial as a treatment for APDS. Novartis has completed all the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
